PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Regulation FD Disclosure
Item 7.01: Regulation FD Disclosure.
PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Regulation FD Disclosure
On November 5, 2019, Pieris Pharmaceuticals, Inc.\’s abstract related to the phase 1 dose escalation study of PRS-343 was released for The Society for Immunotherapy of Cancer\’s (SITC) 34th Annual Meeting. The abstract is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information set forth under this “Item 7.01. Regulation FD Disclosure,” including Exhibit 99.1 attached hereto, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing. except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
99.1 PRS-343 Phase 1 Dose Escalation Study Abstract, Dated November 5, 2019.
PIERIS PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a191105pierisprs343sitca.htm EXHIBIT 99.1 a191105pierisprs343sitca A Phase 1 Dose Escalation Study of PRS-343,…
To view the full exhibit click
EX-99.1 2 a191105pierisprs343sitca.htm EXHIBIT 99.1 a191105pierisprs343sitca A Phase 1 Dose Escalation Study of PRS-343,…
To view the full exhibit click
here
About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.